Last reviewed · How we verify
Ocuzolin (tetryzoline)
At a glance
| Generic name | tetryzoline |
|---|---|
| Sponsor | Fougera Pharms |
| Drug class | tetryzoline |
| Target | Adrenergic receptor alpha |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
- Nasal congestion
- Nasal discharge
- Red eye
Common side effects
Key clinical trials
- Visual and Patient-Reported Outcomes After Bilateral Non-Diffractive EDOF IOL Implantation (NA)
- Comparison of Visual Outcomes and Patient Satisfaction in Mild to Moderate Glaucoma Patients Undergoing Cataract Surgery With EDOF Versus Monofocal IOLs (NA)
- Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy (PHASE2)
- Atropine and Spectacle Combination Treatment (ASPECT): 12-month Results of a Randomized Clinical Trial for Myopia Control (PHASE4)
- Toric Intraocular Lens Implantation for Pediatric Aphakia (NA)
- Amara View Benchmark Study (NA)
- Instant Flush Redness Clinical Efficacy Study (NA)
- Reducing Aerosol and Bioaerosol Using Different Oral Suctions (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ocuzolin CI brief — competitive landscape report
- Ocuzolin updates RSS · CI watch RSS
- Fougera Pharms portfolio CI